Aortic valve replacement in patients aged 50 to 69 years: Analysis using Korean National Big Data

Min-Seok Kim1, Hae Rim Kim2, Seung Hyun Lee3

  • 1Department of Thoracic and Cardiovascular Surgery, Cardiovascular Center, Myongji Hospital, Hanyang University College of Medicine, Seoul, Korea.

Journal of Cardiac Surgery
|September 2, 2022
PubMed

Insights

For patients aged 50-69 undergoing aortic valve replacement (AVR), bioprosthetic valves showed similar long-term survival and cardiac mortality rates compared to mechanical valves. Reoperations were more common with bioprosthetic valves, while bleeding was more frequent with mechanical valves.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Biomaterials Science

Background:

  • Aortic valve replacement (AVR) is a critical procedure for managing aortic valve disease.
  • The choice between mechanical valves and bioprosthetic valves involves balancing long-term durability against risks of anticoagulation and bleeding.

Purpose of the Study:

  • To compare clinical outcomes and long-term survival after isolated AVR in patients aged 50-69 years.
  • To evaluate the comparative effectiveness of mechanical versus bioprosthetic valves in this patient cohort.

Main Methods:

  • A retrospective study using the Korean National Health Information Database (2002-2018).
  • Included 4732 patients aged 50-69 years who underwent isolated AVR.
  • Propensity score-matched analysis created two groups of 1429 patients each: bioprosthetic (Group B) and mechanical (Group M) valves.

Main Results:

  • Overall survival rates at 5 and 10 years were similar between Group B (87.8%, 75.2%) and Group M (91.2%, 76.7%).
  • Freedom from cardiac death rates at 5 and 10 years were also comparable (Group B: 95.6%, 92.4%; Group M: 96.0%, 92.1%).
  • Reoperations were significantly higher in Group B (p=0.007), while major bleeding was higher in Group M (p=0.039).

Conclusions:

  • Bioprosthetic valves demonstrate comparable long-term survival and cardiac mortality-free survival to mechanical valves in patients aged 50-69 undergoing isolated AVR.
  • The choice of valve type influences specific complication risks, with bioprosthetic valves associated with higher reoperation rates and mechanical valves with increased bleeding risk.
Abstract

Related Concept Videos

Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
29
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
37
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
47
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
39
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
28
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
36